• Acadia Pharmaceuticals Inc., of San Diego, said the FDA cleared schizophrenia drug AM-831 to begin a Phase I trial. AM-831 is a small molecule that combines muscarinic m1 partial agonism with dopamine D2 and serotonin 5-HT2A antagonism. The drug was discovered by Acadia and developed in collaboration with Tokyo-based Meiji Seika Kaisha Ltd., under the companies' 2009 antipsychotic deal for Asian territories.